Japan · Delayed Price · Currency is JPY Nxera Pharma Statistics
Total Valuation
Nxera Pharma has a market cap or net worth of JPY 74.84 billion. The enterprise value is 109.52 billion.
| Market Cap | 74.84B |
| Enterprise Value | 109.52B |
Important Dates
The next estimated earnings date is Friday, February 13, 2026.
| Earnings Date | Feb 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nxera Pharma has 90.49 million shares outstanding. The number of shares has increased by 2.21% in one year.
| Current Share Class | 90.49M |
| Shares Outstanding | 90.49M |
| Shares Change (YoY) | +2.21% |
| Shares Change (QoQ) | +0.32% |
| Owned by Insiders (%) | 10.84% |
| Owned by Institutions (%) | 19.56% |
| Float | 73.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 18.36 |
| PS Ratio | 2.61 |
| PB Ratio | 1.14 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -17.83 |
| EV / Sales | 3.82 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -7.84 |
Financial Position
The company has a current ratio of 3.14, with a Debt / Equity ratio of 0.96.
| Current Ratio | 3.14 |
| Quick Ratio | 2.34 |
| Debt / Equity | 0.96 |
| Debt / EBITDA | n/a |
| Debt / FCF | -4.52 |
| Interest Coverage | -4.43 |
Financial Efficiency
Return on equity (ROE) is -9.21% and return on invested capital (ROIC) is -8.57%.
| Return on Equity (ROE) | -9.21% |
| Return on Assets (ROA) | -3.58% |
| Return on Invested Capital (ROIC) | -8.57% |
| Return on Capital Employed (ROCE) | -6.64% |
| Weighted Average Cost of Capital (WACC) | 3.21% |
| Revenue Per Employee | 74.74M |
| Profits Per Employee | -16.00M |
| Employee Count | 384 |
| Asset Turnover | 0.19 |
| Inventory Turnover | 1.47 |
Taxes
| Income Tax | -3.06B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -12.38% in the last 52 weeks. The beta is -0.07, so Nxera Pharma's price volatility has been lower than the market average.
| Beta (5Y) | -0.07 |
| 52-Week Price Change | -12.38% |
| 50-Day Moving Average | 834.78 |
| 200-Day Moving Average | 888.27 |
| Relative Strength Index (RSI) | 49.83 |
| Average Volume (20 Days) | 683,315 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Nxera Pharma had revenue of JPY 28.70 billion and -6.14 billion in losses. Loss per share was -68.17.
| Revenue | 28.70B |
| Gross Profit | 20.43B |
| Operating Income | -8.48B |
| Pretax Income | -9.21B |
| Net Income | -6.14B |
| EBITDA | -4.20B |
| EBIT | -8.48B |
| Loss Per Share | -68.17 |
Balance Sheet
The company has 28.46 billion in cash and 63.14 billion in debt, with a net cash position of -34.68 billion or -383.22 per share.
| Cash & Cash Equivalents | 28.46B |
| Total Debt | 63.14B |
| Net Cash | -34.68B |
| Net Cash Per Share | -383.22 |
| Equity (Book Value) | 65.66B |
| Book Value Per Share | 725.52 |
| Working Capital | 34.99B |
Cash Flow
In the last 12 months, operating cash flow was -13.51 billion and capital expenditures -454.00 million, giving a free cash flow of -13.97 billion.
| Operating Cash Flow | -13.51B |
| Capital Expenditures | -454.00M |
| Free Cash Flow | -13.97B |
| FCF Per Share | -154.34 |
Margins
Gross margin is 71.17%, with operating and profit margins of -29.56% and -21.41%.
| Gross Margin | 71.17% |
| Operating Margin | -29.56% |
| Pretax Margin | -32.08% |
| Profit Margin | -21.41% |
| EBITDA Margin | -14.63% |
| EBIT Margin | -29.56% |
| FCF Margin | n/a |
Dividends & Yields
Nxera Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.21% |
| Shareholder Yield | -2.21% |
| Earnings Yield | -8.21% |
| FCF Yield | -18.66% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 27, 2018. It was a forward split with a ratio of 4.
| Last Split Date | Jun 27, 2018 |
| Split Type | Forward |
| Split Ratio | 4 |
Scores
Nxera Pharma has an Altman Z-Score of 0.85 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.85 |
| Piotroski F-Score | 1 |